[Investigation of mechanisms of action of growth factors of autologous platelet-rich plasma used to treat erectile dysfunction].

AIM: To determine the quantitative and qualitative composition of growth factors (PDGF-AA, PDGF-BB, VEGF, VEGF-D, FGF-acid, FGF-basic) and platelets in various modifications of APRP. MATERIALS AND METHODS: Blood of 12 male volunteers (control group) and 12 patients with ED was used to prepare APRP and the subsequently determine the concentration of growth factors. The growth factor concentrations (FGF acid, FGF basic, PDGF-AA, PDGF-BB, VEGF, VEGF-D) was determined using a flow cytometry-based xMAP Luminex (Gen-Probe) system. RESULTS: Concentration of platelets in APRP obtained by two stage centrifugation, reached 1480 (1120-1644) in the control group and 1232 (956-1502) in patients with ED. The concentration of growth factors in the samples prepared without preliminary freezing was: PDGF-AA 842 (22-3700), PDGF-BB 2837 (1460-4100), FGF-basic 7.9 (0.28-127), FGF-acid 3, 4 (0.14-11), VEGF 19 (4.6-46), VEGF-D 21 (14-38). After thawing, the concentration of all growth factors in the samples increased. DISCUSSION: The study findings suggest that the mechanism of erectile function recovery following the use of APRP is through the active substances detected in APRP, i.e. FGF-basic, PDGF-AA, PDGF-BB, VEGF, VEGF-D and FGF-acid. Also, the study showed that the content of growth factors in APRP after of freezing/thawing is higher than in APRP that has not been frozen. This is due to the cell membrane destruction at extremely low temperatures during freezing.

[Cell technologies' application in practical andrology].

The article is devoted to new methods for treating men's erectile dysfunction using platelet-rich auto plasma and adipose tissue stromal vascular fraction. Recently, there has been increased interest in these methods due to their high level of efficiency and safety. Platelet-rich auto plasma and adipose tissue stromal vascular fraction have been successfully applied in different medical fields - traumatology, orthopedics, plastic surgery, etc. At the same time, efficacy and safety of these technologies has not yet been clinically studied from the perspective of evidence-based medicine.

[THE EFFECTIVENESS OF INTRACAVERNOUS AUTOLOGOUS PLATELET-RICH PLASMA IN THE TREATMENT OF ERECTILE DYSFUNCTION].

This article deals with using autologous platelet-rich plasma (APRP) as a new treatment for erectile dysfunction in men. In recent years there was a significant interest in regenerative medicine technology due to its high effectiveness with a good safety and low cost. Currently APRP has been used successfully in various fields of medicine (surgery, traumatology and orthopedics, sports medicine, cosmetics). However, until now there have been no studies consistent with evidence-based medicine verifying the effectiveness and long-term results of APRP application for ED treatment. This article presents the results of a clinical study on the use of APRP in men with ED with a comparative effectiveness analysis of different ways of APRP administration and in combination with PDE5 inhibitors. Possible mechanisms of action of APRP in restoring erectile function are discussed.

[APPLICATION OF AUTOPLASMA ENRICHED WITH PLATELET DERIVED GROWTH FACTOR IN THE TREATMENT OF ERECTILE DYSFUNCTION].

Autoplasma enriched with platelet derived growth factor (AET) is a technology that is included in the scope of regenerative medicine. The main active component of AET is biologically active substance - of growth factors, cytokines and chemokines involved in cell growth, proliferation and cell differentiation in accordance with the tissue species specifity. This article presents information on ingredients of autoplasma, classification of AET preparations; the possible mechanisms of action are discussed, and the results of pre-clinical and clinical trials of AET in various diseases, including erectile dysfunction, are also reviewed.

[Prospects for application of stem cells from adipose tissue in treating erectile dysfunction].

Although phosphodiesterase type 5 inhibitors are the first-line treatment of ED, some patients remain unresponsive to any pharmacotherapy. To date, the use of stem cells is considered as a new treatment modality for erectile dysfunction. The validity of this assumption has been experimentally proved in preclinical and clinical studies. The main focus is on the stem cells derived from adipose tissue, due to advantages over other sources.